Unquoted Biotechs Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Unquoted Biotechs

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: nigel bates	6/11/2006 4:06:51 PM
	of 253

Amyris Biotechnologies is focused on translating the promise of synthetic biology into solutions for real-world problems.... amyrisbiotech.com ...Amyris uses engineered microbes and rapid enzymatic pathway construction techniques to build microorganisms capable of producing high-value, bioactive compounds important in many pharmaceuticals and fine chemicals. Our microbial production system enables the reliable and cost-effective production of a large class of natural chemicals known as isoprenoids that are currently available in only very small quantities from natural sources. The biotechnology of microbial production underpinning Amyris' approach was developed at the University of California, Berkeley, in the laboratory of Professor Jay Keasling and published in July 2003 in Nature Biotechnology. Dr. Keasling developed a platform technology for transplanting yeast and plant genes into E. coli bacteria to construct an entirely new metabolic pathway, enabling the synthesis of a copious supply of isoprenoid precursors. These precursors can then be converted to any isoprenoid product of choice through the addition of a specific biosynthetic gene (synthase). This "plug and play" method of microbial isoprenoid production represents a breakthough in synthetic biology and provides a broad product platform technology for Amyris. We are working with Professor Keasling's laboratory and the Berkeley Center for Synthetic Biology to develop novel methods for discovering new synthases for our production strains, broadening our opportunities for producing chemicals currently only available from natural sources. Furthermore, high-throughput screening and protein engineering may allow the extension of this technology to non-natural chemicals. We have in-licensed patents from UC Berkeley to protect our current inventions and plan to file additional patent applications to cover our different microbial production strains as they are made...

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next